title: Gene expression profiling of chronic myeloid leukemia with variant t(9;22) reveals a different signature from cases with classic translocation.
abstract: BACKGROUND
  The t(9;22)(q34;q11) generating the BCR/ABL1 fusion gene represents the cytogenetic hallmark of chronic myeloid leukemia (CML). About 5-10% of CML cases show variant translocations with the involvement of other chromosomes in addition to chromosomes 9 and 22. The molecular bases of biological differences between CML patients with classic and variant t(9;22) have never been clarified.
  
  
  RESULTS
  In this study, we performed gene expression microarray analysis to compare CML patients bearing variant rearrangements and those with classic t(9;22)(q34;q11). We identified 59 differentially expressed genes significantly associated with the two analyzed groups. The role of specific candidate genes such as TRIB1 (tribbles homolog 1), PTK2B (protein tyrosine kinase 2 beta), and C5AR1 (complement component 5a receptor 1) is discussed.
  
  
  CONCLUSIONS
  Our results reveal that in CML cases with variant t(9;22) there is an enhancement of the MAPK pathway deregulation and show that kinases are a common target of molecular alterations in hematological disorders.
authors: Department of Emergency and Organ Transplantation-Hematology Section, University of Bari, Bari, Italy. francesco.albano@uniba.it
authors: Francesco
authors: F
authors: Albano
authors: Antonella
authors: A
authors: Zagaria
authors: Luisa
authors: L
authors: Anelli
authors: Nicoletta
authors: N
authors: Coccaro
authors: Luciana
authors: L
authors: Impera
authors: Crescenzio Francesco
authors: CF
authors: Minervini
authors: Angela
authors: A
authors: Minervini
authors: Antonella Russo
authors: AR
authors: Rossi
authors: Giuseppina
authors: G
authors: Tota
authors: Paola
authors: P
authors: Casieri
authors: Giorgina
authors: G
authors: Specchia
mesh_terms: D002892:Chromosomes, Human, Pair 22; D002899:Chromosomes, Human, Pair 9; D016000:Cluster Analysis; D020869:Gene Expression Profiling; D015973:Gene Expression Regulation, Leukemic; D053263:Gene Regulatory Networks; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000378:metabolism; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D010770:Phosphotransferases / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction; D014178:Translocation, Genetic
chemical_list: D010770:Phosphotransferases; D020928:Mitogen-Activated Protein Kinases; D016283:Proto-Oncogene Proteins p21(ras)
references: Nat Rev Cancer. 2007 Jun;7(6):441-53
references: 17522713
references: N Engl J Med. 2003 Oct 9;349(15):1451-64
references: 14534339
references: Blood. 2011 Jun 23;117(25):6793-800
references: 21447834
references: Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2794-9
references: 16477019
references: Blood. 2010 Oct 14;116(15):2768-75
references: 20610816
references: Leukemia. 2006 Jun;20(6):1047-54
references: 16598311
references: Mol Cancer. 2010 May 25;9:120
references: 20500819
references: Cancer Genet Cytogenet. 2004 Apr 1;150(1):81-5
references: 15041230
references: Clin Cancer Res. 2012 Feb 15;18(4):930-7
references: 22156549
references: Am J Physiol Cell Physiol. 2012 Jun 15;302(12):C1731-40
references: 22496247
references: Blood. 2001 Sep 15;98(6):1732-8
references: 11535505
references: FASEB J. 2004 Jul;18(10):1060-70
references: 15226266
references: Leuk Lymphoma. 2006 Mar;47(3):397-402
references: 16396761